haematology

Low-dose haloperidol still first line for cancer nausea

Low-dose haloperidol should be considered the first-line agent in cancer patients with ongoing nausea that is not related to their anticancer treatment, Australian researchers say. A randomised-controlled trial of methotrimeprazine versus haloperidol in 11 palliative care sites around Australian found similar response rates between the two drugs. The trial involved 121 adult cancer patients with ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic